Argitalpenak (164) EDUARDO FERNÁNDEZ-CRUZ PÉREZ argitalpenak

2022

  1. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

    The Lancet Infectious Diseases, Vol. 22, Núm. 5, pp. 622-635

  2. Evolution and molecular interactions of major histocompatibility complex (MHC)-G, -E and -F genes

    Cellular and Molecular Life Sciences, Vol. 79, Núm. 8

  3. HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease

    Frontiers in Immunology, Vol. 13

  4. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

    The Lancet, Vol. 399, Núm. 10324, pp. 530-540

  5. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 10, Núm. 10, pp. 972-984

2021

  1. HLA-G 3’UTR Polymorphisms Are Linked to Susceptibility and Survival in Spanish Gastric Adenocarcinoma Patients

    Frontiers in Immunology, Vol. 12

  2. HLA-G in Mayas from Yucatan: An evolutionary approach

    International Journal of Immunogenetics, Vol. 48, Núm. 5, pp. 403-408

  3. Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain

    Clinical and Experimental Immunology, Vol. 203, Núm. 3, pp. 424-432

2019

  1. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

    The Lancet Respiratory Medicine, Vol. 7, Núm. 11, pp. 951-963

2018

  1. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study

    Journal of Heart and Lung Transplantation, Vol. 36, Núm. 5, pp. 529-539

  2. Impact of the polymorphism rs9264942 near the HLA-C gene on HIV-1 DNA reservoirs in asymptomatic chronically infected patients initiating antiviral therapy

    Journal of Immunology Research, Vol. 2017

2016

  1. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial

    Transplant Infectious Disease, Vol. 18, Núm. 6, pp. 832-843

  2. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency

    Clinical Immunology, Vol. 169, pp. 80-84

  3. Peripheral blood T- and B-cell immunophenotypic abnormalities in selected women with unexplained recurrent miscarriage

    Journal of Reproductive Immunology, Vol. 113, pp. 50-53

2015

  1. Audit of the use of intravenous immunoglobulin for antibody deficiencies in a Clinical Immunology Unit

    Allergologia et Immunopathologia

  2. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  3. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion

    American Journal of Reproductive Immunology, Vol. 71, Núm. 5, pp. 458-466

2013

  1. Alterations of naïve and memory B-cell subsets are associated with risk of rejection and infection in heart recipients

    Transplant International, Vol. 26, Núm. 8, pp. 800-812